Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Also another $22,684.86 is sitting at .0011 ready to move up if needed. As long as whoever can get filled at .0011 is doing so good for them cant blame them one bit. It wont last long though.
For sure.. But on the other hand $47,223.17 in 12s have been scooped up today.. Were going to be good to go soon. IMO..
Yesterdays $MJTK News.. Will look cheap very soon!!
Denver, Colorado (PRWEB) September 19, 2017
CannaSys, a marketing, branding, and technology company, today announced its first marketing promotion in the cannabinoid (“CBD”) market, in partnership with independent coffee maker Sträva Craft Coffee, Inc. and leading cannabis social media application Duby, LLC. The ad will be targeted at more than 200,000 consumers nationwide, the first of its kind in the CBD marketplace, which is growing at more than 30% per year with expected sales of nearly $1 billion in 2017 according to The Hemp Business Journal “State of Hemp 2017 Market Report.”
Initial responses have been strong from a beta test text blast Citizen Toke promoted with Sträva Craft Coffee. As a result, CannaSys is expanding the promotion through its partnership with Duby, LLC, one of the social media applications targeting cannabis consumers through a global platform.
Patrick Burke, CannaSys’s Chief Executive Officer, commented: “We are very excited to launch Citizen Toke into the CBD industry, using digital media to break down the geographically limited marketing barriers that hamper traditional cannabis businesses. We believe the CBD market, which is growing as fast or faster than the regulated cannabis market, is a perfect product platform to leverage Citizen Toke, and we look forward to launching future promotions.”
Citizen Toke offers exclusive, instant, location-based, gamified promotions for cannabis retailers looking to more intimately connect with their consumers directly through SMS. Citizen Toke is an efficient means for retail centers to communicate exclusive promotions to their consumers and to extend brand awareness to current and potentially new customers. More details on the technology and business plan of Citizen Toke can be found in our White Paper.
CannaSys and its board and senior management remain committed to creating long-term shareholder value and will provide timely updates to shareholders as they occur.
About CannaSys, Inc.
CannaSys is a technology solutions, marketing, and branding company. Its core products are delivered “software as a service” to facilitate point-of-purchase transactions and customer relationship marketing solutions. CannaSys plans to develop, acquire, and build strategic relationships with other businesses in order to bring additional solutions to market. For more information, please visit http://www.cannasys.com and http://www.citizentoke.com.
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including continued acceptance of CannaSys’s products, increased levels of competition for CannaSys, new products and technological changes, CannaSys’s dependence on third-party suppliers, and other risks detailed from time to time in CannaSys’s periodic reports filed with the U.S. Securities and Exchange Commission.
Yesterdays $MJTK News.. Will look cheap very soon!!
Denver, Colorado (PRWEB) September 19, 2017
CannaSys, a marketing, branding, and technology company, today announced its first marketing promotion in the cannabinoid (“CBD”) market, in partnership with independent coffee maker Sträva Craft Coffee, Inc. and leading cannabis social media application Duby, LLC. The ad will be targeted at more than 200,000 consumers nationwide, the first of its kind in the CBD marketplace, which is growing at more than 30% per year with expected sales of nearly $1 billion in 2017 according to The Hemp Business Journal “State of Hemp 2017 Market Report.”
Initial responses have been strong from a beta test text blast Citizen Toke promoted with Sträva Craft Coffee. As a result, CannaSys is expanding the promotion through its partnership with Duby, LLC, one of the social media applications targeting cannabis consumers through a global platform.
Patrick Burke, CannaSys’s Chief Executive Officer, commented: “We are very excited to launch Citizen Toke into the CBD industry, using digital media to break down the geographically limited marketing barriers that hamper traditional cannabis businesses. We believe the CBD market, which is growing as fast or faster than the regulated cannabis market, is a perfect product platform to leverage Citizen Toke, and we look forward to launching future promotions.”
Citizen Toke offers exclusive, instant, location-based, gamified promotions for cannabis retailers looking to more intimately connect with their consumers directly through SMS. Citizen Toke is an efficient means for retail centers to communicate exclusive promotions to their consumers and to extend brand awareness to current and potentially new customers. More details on the technology and business plan of Citizen Toke can be found in our White Paper.
CannaSys and its board and senior management remain committed to creating long-term shareholder value and will provide timely updates to shareholders as they occur.
About CannaSys, Inc.
CannaSys is a technology solutions, marketing, and branding company. Its core products are delivered “software as a service” to facilitate point-of-purchase transactions and customer relationship marketing solutions. CannaSys plans to develop, acquire, and build strategic relationships with other businesses in order to bring additional solutions to market. For more information, please visit http://www.cannasys.com and http://www.citizentoke.com.
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including continued acceptance of CannaSys’s products, increased levels of competition for CannaSys, new products and technological changes, CannaSys’s dependence on third-party suppliers, and other risks detailed from time to time in CannaSys’s periodic reports filed with the U.S. Securities and Exchange Commission.
.0012s going to look cheap in a few weeks. Just need to give it some time funds are flowing in from alot of other MJ winners around the OTC.
Don't let the negative Nancy's scare you out of your shares. Slow and steady wins the race here and its been getting accumulated nicely.. GLTA
MJTK News
MONEY® News
CannaSys’s Product Citizen Toke Releases First Consumer Promotion Targeted at Rapidly Growing CBD Market
September 19, 2017 PRWeb Computers and Software, Economic Trends, Financial Services, General News, Manufacturing and Production, Media and Entertainment, Multimedia/Internet/Online Services, Professional Services, Retail, Science, Stock/Other Market News
Denver, Colorado (PRWEB) September 19, 2017
CannaSys, a marketing, branding, and technology company, today announced its first marketing promotion in the cannabinoid (“CBD”) market, in partnership with independent coffee maker Sträva Craft Coffee, Inc. and leading cannabis social media application Duby, LLC. The ad will be targeted at more than 200,000 consumers nationwide, the first of its kind in the CBD marketplace, which is growing at more than 30% per year with expected sales of nearly $1 billion in 2017 according to The Hemp Business Journal “State of Hemp 2017 Market Report.”
Initial responses have been strong from a beta test text blast Citizen Toke promoted with Sträva Craft Coffee. As a result, CannaSys is expanding the promotion through its partnership with Duby, LLC, one of the social media applications targeting cannabis consumers through a global platform.
Patrick Burke, CannaSys’s Chief Executive Officer, commented: “We are very excited to launch Citizen Toke into the CBD industry, using digital media to break down the geographically limited marketing barriers that hamper traditional cannabis businesses. We believe the CBD market, which is growing as fast or faster than the regulated cannabis market, is a perfect product platform to leverage Citizen Toke, and we look forward to launching future promotions.”
Citizen Toke offers exclusive, instant, location-based, gamified promotions for cannabis retailers looking to more intimately connect with their consumers directly through SMS. Citizen Toke is an efficient means for retail centers to communicate exclusive promotions to their consumers and to extend brand awareness to current and potentially new customers. More details on the technology and business plan of Citizen Toke can be found in our White Paper.
CannaSys and its board and senior management remain committed to creating long-term shareholder value and will provide timely updates to shareholders as they occur.
About CannaSys, Inc.
CannaSys is a technology solutions, marketing, and branding company. Its core products are delivered “software as a service” to facilitate point-of-purchase transactions and customer relationship marketing solutions. CannaSys plans to develop, acquire, and build strategic relationships with other businesses in order to bring additional solutions to market. For more information, please visit http://www.cannasys.com and http://www.citizentoke.com.
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including continued acceptance of CannaSys’s products, increased levels of competition for CannaSys, new products and technological changes, CannaSys’s dependence on third-party suppliers, and other risks detailed from time to time in CannaSys’s periodic reports filed with the U.S. Securities and Exchange Commission.
Read the full story at http://www.prweb.com/releases/2017/09/prweb14708150.htm
Share this:
Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window)Click to share on Google+ (Opens in new window)
Related
Senate Appropriations Committee Action Adds Fuel to the Fire for Businesses in the Legal Cannabis SpaceAugust 2, 2017In "Investment Opinion"
The Hemp CBD Market Projected to SurgeSeptember 18, 2017In "Financial Services"
Sales of CBD and Hemp Products are Projected to GrowJuly 24, 2017In "Investment Opinion"
Leave a Reply
Your email address will not be published. Required fields are marked *
Comment
Name *
Email *
Website
Notify me of follow-up comments by email.
Notify me of new posts by email.
Post navigation
SavATree Lawn Experts Advise That Fall 2017 Presents Optimal Conditions for Seeding Lawns
Take Me Home Huey to Premiere on PBS SoCal KOCE
MEDIA PARTNERS
CNW News and Press Releases
Globenewswire News and Press Releases
Marketwired News and Press Releases
PRNewswire News and Press Releases
PRWeb News and Press Releases
:)
Skip to main content
MONEY® News
CannaSys’s Product Citizen Toke Releases First Consumer Promotion Targeted at Rapidly Growing CBD Market
September 19, 2017 PRWeb Computers and Software, Economic Trends, Financial Services, General News, Manufacturing and Production, Media and Entertainment, Multimedia/Internet/Online) Services, Professional Services, Retail, Science, Stock/Other Market News
Denver, Colorado (PRWEB) September 19, 2017
CannaSys, a marketing, branding, and technology company, today announced its first marketing promotion in the cannabinoid (“CBD”) market, in partnership with independent coffee maker Sträva Craft Coffee, Inc. and leading cannabis social media application Duby, LLC. The ad will be targeted at more than 200,000 consumers nationwide, the first of its kind in the CBD marketplace, which is growing at more than 30% per year with expected sales of nearly $1 billion in 2017 according to The Hemp Business Journal “State of Hemp 2017 Market Report.”
Initial responses have been strong from a beta test text blast Citizen Toke promoted with Sträva Craft Coffee. As a result, CannaSys is expanding the promotion through its partnership with Duby, LLC, one of the social media applications targeting cannabis consumers through a global platform.
Patrick Burke, CannaSys’s Chief Executive Officer, commented: “We are very excited to launch Citizen Toke into the CBD industry, using digital media to break down the geographically limited marketing barriers that hamper traditional cannabis businesses. We believe the CBD market, which is growing as fast or faster than the regulated cannabis market, is a perfect product platform to leverage Citizen Toke, and we look forward to launching future promotions.”
Citizen Toke offers exclusive, instant, location-based, gamified promotions for cannabis retailers looking to more intimately connect with their consumers directly through SMS. Citizen Toke is an efficient means for retail centers to communicate exclusive promotions to their consumers and to extend brand awareness to current and potentially new customers. More details on the technology and business plan of Citizen Toke can be found in our White Paper.
CannaSys and its board and senior management remain committed to creating long-term shareholder value and will provide timely updates to shareholders as they occur.
About CannaSys, Inc.
CannaSys is a technology solutions, marketing, and branding company. Its core products are delivered “software as a service” to facilitate point-of-purchase transactions and customer relationship marketing solutions. CannaSys plans to develop, acquire, and build strategic relationships with other businesses in order to bring additional solutions to market. For more information, please visit http://www.cannasys.com and http://www.citizentoke.com.
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including continued acceptance of CannaSys’s products, increased levels of competition for CannaSys, new products and technological changes, CannaSys’s dependence on third-party suppliers, and other risks detailed from time to time in CannaSys’s periodic reports filed with the U.S. Securities and Exchange Commission.
MJTK Wound Tight 23mil x 5Mil
Setting up nicely Keep up the buying pressure. The run starts as soon as the 22mil on the bid realizes they might not get filled.. Just step your buys up and we lift off!!
MJTK 32MILL BID VS 2MILL ASK bottoms in might want to get some for the next run. GLTA
MJTK bottom 32mil x 2 mil Get Ready
MJTK 30mil x 2mil bottom back in.
MJTK quietly getting accumulated 20mil X 6Mil GLTA
Quietly accumulating..
MJTK looks cheap!
Another great day.. More to come I hope.
Time to accumulate again!!
Cantech Holding, Inc. (BSSP) Announces Formal Negotiations for LOI/Business Collaboration With Zelor S.A.P.I., Mexico
12:53 PM ET 8/19/16 | Marketwired
MONROVIA, CA--(Marketwired - Aug 19, 2016) - Cantech Holding, Inc., formerly Reve Technologies, Inc., (OTC PINK: BSSP) (the "Company" or "Cantech") a development stage immunotherapeutic based technology company today announced it has received a Letter of Intent which proposes a business collaboration with newly formed Institute of Medicine of the conservation ZELOR S.A.P.I., located in Tijuana, B.C., Mexico ("Zelor").
After ongoing discussions on August 16, 2016 the Company received a letter of intent from Zelor who is involved with scientific research on biotechnology field specializing in human health. Zelor has expressed interest standing ready to discuss business collaboration and terms for processing and/or manufacturing of Cantechs spotlight product called Immune Therapeutic Protein as well as specific process and/or requirements for the Company's objectives. Zelor describes their terms of collaboration attractive and facilities accommodating including state of the art equipment and GMP (good manufacturing practices) all around. Company management will attend the now scheduled formal meeting in Mexico early next week. The onsite visit to include to view and inspect the facilities while attending the formal negotiations for the proposed business collaboration agreement between the Company and Zelor which have been discussed to include the processing and/or manufacture for commercialization of its spotlight product utilizing Zelors facilities and utilizing its permit for Mexico.
The Company notes it will additionally pursue the completion for obtaining its own permit in progress for over eight months now but believes that the business collaboration with Zelor upon completion steps up and provides for the sooner immediate entry to the markets for initiation of the Companys spotlight product in Mexico.
Further the Company reports that it is also in negotiations to obtain licensing from a Company that has an FDA, Medicare and Medi Cal approved medical device technology for non-invasive cardio vascular testing procedures and other important medical testing applications.
The Company previously reported launching its new corporate identity as Cantech to reflect is new business strategy. The name represents the fusion of an innovative approach regarding its commitment to improving lives by helping to bring impactful immunotherapeutic treatment(s) to market initially in Mexico for cancer indication.
The Company previously reported it was in process of obtaining an assignment for a new cusip number in connection with the name change, and its submission of a corporate action with FINRA toward gaining approval regarding a new ticker symbol for the Company as soon as practicable and plans to announce any effective date for such change in a future release or current report. The corporate action included the Company changing both its name to Cantech Holding, Inc. from Reve Technologies, Inc. along with changing its corporate domicile to Wyoming from Nevada which all became effective on May 27, 2016, and provided for a voluntary symbol change requested. The Company further notes that its filings going forward on the next filing with the SEC will also track under the new name Cantech Holding, Inc. On August 5, 2016 the Company received notice from FINRA summarily that after review of the corporate action including all materials submitted, and including its periodic reports, that in accordance with FINRA rule 6490 it was deficient under said rule citing the Company being delinquent in two of its periodic reports for the period ended December 31, 2015, and for the period ended March 31, 2016. Once the filing deficiencies have been cured the Company may resubmit the corporate action which would then upon any subsequent approval allow OTC markets to finally recognize the name change that presently exists everywhere else (already effective in Wyoming and on the next filing to the SEC EDGAR database) along with providing for a new symbol to match. Noting, the Company believes it has encountered difficulties through the review period from certain potential investors that would have assisted much earlier the additional financing necessary to assist curing the delinquencies and provide additional working capital for Company operations but however required the symbol and name be processed simply to match its new business operations and Cantech name going forward for the OTC markets which the Company believes is logical. The Company will endeavor to proceed forward with these obstacles as best possible.
About Canteck Pharma, Inc. IPF for Cancer treatment
Immunotherapy has the potential to provide an alternative and/or complementary treatment in combination with other immune base therapy for several types of cancer. The advantage of immunotherapy over radiation and chemotherapy is that it can act specifically against the tumor without causing normal tissue damage. Current data indicates that immune protection against all cancer requires the generation of a potent cellular immune response against a unique tumor antigen expressed by the malignant cell. As a consequence successful immune protection first requires a unique antigen expressed in the tumor cells (tumor specific antigen) and second, an induction of a potent T-cell immune response, targeted to the tumor antigen.
Unfortunately the immune system by itself can't recognize specific tumor antigens and reject them; however recent advances have revealed that certain proteins binding with specific tumor antigens can be recognized by the immune system, this is what IPF does.
IPF proteins attach to tumor antigens, creating super-antigens (Sags), which increases the number of antibodies against the malignant cells and induces a potent T-cell immune response targeted to the tumor antigen. For a stronger immune response, IPF may be paired with different kinds of adjuvants such as IL-2, IL-6, IL-12 or other cytokines. Another form of immunotherapy can also provide active immunization, which allows for amplification of the immune response. In addition, vaccines can generate a memory immune response. Recent advances have revealed that any cellular protein (expressed in virally infected cells or cancer cells) can be recognized by the immune system if those proteins are presented to the immune system in a form that results in an activation rather than ignorance or tolerance to the antigen. In addition, T-cells rather than B-cells are usually responsible for this recognition.
It is important to point out that when we discuss vaccines for cancer we are referring to treatment rather than prevention, because the antigens expressed by tumor cells (which are the immunogens recognized by the immune system) are not yet known. Attaching known proteins will increase the number of antibodies to fight against them.
This mechanism of action will give us an exact answer (known antigens we have to make known for immune system). In contrast we can use vaccines to prevent infectious diseases because the antigens expressed the causative agent -- fraction and/or its proteins that can attach, serve as the immunogen are already known.
About Cantech Holding, Inc. (f/k/a Reve Technologies, Inc.)
The Company was incorporated on May 11, 2010 (Date of Inception) under the laws of the State of Nevada, as Bassline Productions, Inc. On March 21, 2014 the Company amended its articles of incorporation and changed its name to Reve Technologies, Inc. and investing to develop and market emerging hardware, mobile and web applications later establishing a new Capital Purchase Division. The Company is now a transitioning forward with the acquisition of an Exclusive License Agreement for Patented Technology for Irreversible Pepsin Fraction (IPF) specific to the Cancer indication only, for Mexico with privately held immune-oncology and Therapeutics company. Through the terms for the Company's Exclusive Sub Licensing Agreement with Canteck Pharma, Inc. we will focus on the development, manufacture and commercialize our lead product Irreversible Pepsin Fraction (IPF) specific to the Cancer indication only, for Mexico. The Company changed its name to Cantech Holding, Inc. effective on May 27, 2016 and its domicile to Wyoming from Nevada also effective on May 27, 2016.
Cantech Holding, Inc. (BSSP) Announces Formal Negotiations for LOI/Business Collaboration With Zelor S.A.P.I., Mexico
12:53 PM ET 8/19/16 | Marketwired
MONROVIA, CA--(Marketwired - Aug 19, 2016) - Cantech Holding, Inc., formerly Reve Technologies, Inc., (OTC PINK: BSSP) (the "Company" or "Cantech") a development stage immunotherapeutic based technology company today announced it has received a Letter of Intent which proposes a business collaboration with newly formed Institute of Medicine of the conservation ZELOR S.A.P.I., located in Tijuana, B.C., Mexico ("Zelor").
After ongoing discussions on August 16, 2016 the Company received a letter of intent from Zelor who is involved with scientific research on biotechnology field specializing in human health. Zelor has expressed interest standing ready to discuss business collaboration and terms for processing and/or manufacturing of Cantechs spotlight product called Immune Therapeutic Protein as well as specific process and/or requirements for the Company's objectives. Zelor describes their terms of collaboration attractive and facilities accommodating including state of the art equipment and GMP (good manufacturing practices) all around. Company management will attend the now scheduled formal meeting in Mexico early next week. The onsite visit to include to view and inspect the facilities while attending the formal negotiations for the proposed business collaboration agreement between the Company and Zelor which have been discussed to include the processing and/or manufacture for commercialization of its spotlight product utilizing Zelors facilities and utilizing its permit for Mexico.
The Company notes it will additionally pursue the completion for obtaining its own permit in progress for over eight months now but believes that the business collaboration with Zelor upon completion steps up and provides for the sooner immediate entry to the markets for initiation of the Companys spotlight product in Mexico.
Further the Company reports that it is also in negotiations to obtain licensing from a Company that has an FDA, Medicare and Medi Cal approved medical device technology for non-invasive cardio vascular testing procedures and other important medical testing applications.
The Company previously reported launching its new corporate identity as Cantech to reflect is new business strategy. The name represents the fusion of an innovative approach regarding its commitment to improving lives by helping to bring impactful immunotherapeutic treatment(s) to market initially in Mexico for cancer indication.
The Company previously reported it was in process of obtaining an assignment for a new cusip number in connection with the name change, and its submission of a corporate action with FINRA toward gaining approval regarding a new ticker symbol for the Company as soon as practicable and plans to announce any effective date for such change in a future release or current report. The corporate action included the Company changing both its name to Cantech Holding, Inc. from Reve Technologies, Inc. along with changing its corporate domicile to Wyoming from Nevada which all became effective on May 27, 2016, and provided for a voluntary symbol change requested. The Company further notes that its filings going forward on the next filing with the SEC will also track under the new name Cantech Holding, Inc. On August 5, 2016 the Company received notice from FINRA summarily that after review of the corporate action including all materials submitted, and including its periodic reports, that in accordance with FINRA rule 6490 it was deficient under said rule citing the Company being delinquent in two of its periodic reports for the period ended December 31, 2015, and for the period ended March 31, 2016. Once the filing deficiencies have been cured the Company may resubmit the corporate action which would then upon any subsequent approval allow OTC markets to finally recognize the name change that presently exists everywhere else (already effective in Wyoming and on the next filing to the SEC EDGAR database) along with providing for a new symbol to match. Noting, the Company believes it has encountered difficulties through the review period from certain potential investors that would have assisted much earlier the additional financing necessary to assist curing the delinquencies and provide additional working capital for Company operations but however required the symbol and name be processed simply to match its new business operations and Cantech name going forward for the OTC markets which the Company believes is logical. The Company will endeavor to proceed forward with these obstacles as best possible.
About Canteck Pharma, Inc. IPF for Cancer treatment
Immunotherapy has the potential to provide an alternative and/or complementary treatment in combination with other immune base therapy for several types of cancer. The advantage of immunotherapy over radiation and chemotherapy is that it can act specifically against the tumor without causing normal tissue damage. Current data indicates that immune protection against all cancer requires the generation of a potent cellular immune response against a unique tumor antigen expressed by the malignant cell. As a consequence successful immune protection first requires a unique antigen expressed in the tumor cells (tumor specific antigen) and second, an induction of a potent T-cell immune response, targeted to the tumor antigen.
Unfortunately the immune system by itself can't recognize specific tumor antigens and reject them; however recent advances have revealed that certain proteins binding with specific tumor antigens can be recognized by the immune system, this is what IPF does.
IPF proteins attach to tumor antigens, creating super-antigens (Sags), which increases the number of antibodies against the malignant cells and induces a potent T-cell immune response targeted to the tumor antigen. For a stronger immune response, IPF may be paired with different kinds of adjuvants such as IL-2, IL-6, IL-12 or other cytokines. Another form of immunotherapy can also provide active immunization, which allows for amplification of the immune response. In addition, vaccines can generate a memory immune response. Recent advances have revealed that any cellular protein (expressed in virally infected cells or cancer cells) can be recognized by the immune system if those proteins are presented to the immune system in a form that results in an activation rather than ignorance or tolerance to the antigen. In addition, T-cells rather than B-cells are usually responsible for this recognition.
It is important to point out that when we discuss vaccines for cancer we are referring to treatment rather than prevention, because the antigens expressed by tumor cells (which are the immunogens recognized by the immune system) are not yet known. Attaching known proteins will increase the number of antibodies to fight against them.
This mechanism of action will give us an exact answer (known antigens we have to make known for immune system). In contrast we can use vaccines to prevent infectious diseases because the antigens expressed the causative agent -- fraction and/or its proteins that can attach, serve as the immunogen are already known.
About Cantech Holding, Inc. (f/k/a Reve Technologies, Inc.)
The Company was incorporated on May 11, 2010 (Date of Inception) under the laws of the State of Nevada, as Bassline Productions, Inc. On March 21, 2014 the Company amended its articles of incorporation and changed its name to Reve Technologies, Inc. and investing to develop and market emerging hardware, mobile and web applications later establishing a new Capital Purchase Division. The Company is now a transitioning forward with the acquisition of an Exclusive License Agreement for Patented Technology for Irreversible Pepsin Fraction (IPF) specific to the Cancer indication only, for Mexico with privately held immune-oncology and Therapeutics company. Through the terms for the Company's Exclusive Sub Licensing Agreement with Canteck Pharma, Inc. we will focus on the development, manufacture and commercialize our lead product Irreversible Pepsin Fraction (IPF) specific to the Cancer indication only, for Mexico. The Company changed its name to Cantech Holding, Inc. effective on May 27, 2016 and its domicile to Wyoming from Nevada also effective on May 27, 2016.
Big things coming soon!!!
Sure why not nothing concrete to do other wise. Just set your sell order and fugetaboutit.. lol
I just moved my sell order way up. She's due for some news.
Maybe it will go up right after, that always happens to me.. GL
Still here updates soon!!
ARCS on radar!!
Inflow just starting updates on the way!!! GLTA
This is the week we've been waiting for!!
not at all ask is thinner as well and could get a bit back with one whale adding.. I feel a tidal wave coming here very soon.
LOL Vol before price and we got some nice hits coming in today. People are loading and will be rewarded soon or later!! GLTA
Yep this time much higher!!! IMHO
BSSP setting up for the next run. More updates coming soon!!
BSSP setting up for the next run. More updates coming soon!!
Setting up again for the next run..
That means nothing just that the PPS has been recycling here until now and soon BSSP will make a huge run north.. GLTA Word is getting out on the deals being made here soon we will get an update on sales and rev.. then explosion.. IMHO
http://www.cantechholding.com/posts/ Real deals developing BSSP
Thank you for your interest in Medibiologica/Biomedical Cancer Center. We treat several diseases, including cancer, in an alternative and more natural way that is much less invasive for the body compared to other treatments. Our main protocol for cancer patients is immunotherapy, which is composed by different stages that include therapies such as vitamins, ozone, dentritic cells, natural killer and autologous cytokines that activate the immune system. Our realtionship with Cantech Holding is that they are part of our immunotherapy protocol at the moment that we give our patients their Immune-Therapeutic Protein (ITp) for our patients to continue the treatment back home. This is in order for the patient to keep up with a maintenance phase and continue activating their immune system.
If you are interested in our treatments, we kindly ask you to read more information about us in our website www.biomedicalcancercenter.com or send us an email with a medical history of the patient interested so we can give a more personalized protocol that is adequate for their condition.
We hope this information was helpful, please do not hesitate in contacting us if you have any further questions or concerns, we are happy to help.
Kind regards,
Cordialmente,
DR. JOSE RICARDO DUEÑAS . / Dra. GINA M. CASTELLANOS B.
Medicina Biológica Integrativa - Homotoxicología - Nutrición Clínica
Anti Envejecimiento - Medicina Estética
Consultorio: (664) 686 3177 - FROM U.S.A. (619) 270 5525
Calle Diego Rivera 2351, Cons. 604 - Zona Rio
Tijuana, B.C, Mexico 22010
http://www.cantechholding.com/posts/ Real deals developing BSSP
Thank you for your interest in Medibiologica/Biomedical Cancer Center. We treat several diseases, including cancer, in an alternative and more natural way that is much less invasive for the body compared to other treatments. Our main protocol for cancer patients is immunotherapy, which is composed by different stages that include therapies such as vitamins, ozone, dentritic cells, natural killer and autologous cytokines that activate the immune system. Our realtionship with Cantech Holding is that they are part of our immunotherapy protocol at the moment that we give our patients their Immune-Therapeutic Protein (ITp) for our patients to continue the treatment back home. This is in order for the patient to keep up with a maintenance phase and continue activating their immune system.
If you are interested in our treatments, we kindly ask you to read more information about us in our website www.biomedicalcancercenter.com or send us an email with a medical history of the patient interested so we can give a more personalized protocol that is adequate for their condition.
We hope this information was helpful, please do not hesitate in contacting us if you have any further questions or concerns, we are happy to help.
Kind regards,
Cordialmente,
DR. JOSE RICARDO DUEÑAS . / Dra. GINA M. CASTELLANOS B.
Medicina Biológica Integrativa - Homotoxicología - Nutrición Clínica
Anti Envejecimiento - Medicina Estética
Consultorio: (664) 686 3177 - FROM U.S.A. (619) 270 5525
Calle Diego Rivera 2351, Cons. 604 - Zona Rio
Tijuana, B.C, Mexico 22010
http://www.cantechholding.com/posts/ Real deals developing BSSP
Thank you for your interest in Medibiologica/Biomedical Cancer Center. We treat several diseases, including cancer, in an alternative and more natural way that is much less invasive for the body compared to other treatments. Our main protocol for cancer patients is immunotherapy, which is composed by different stages that include therapies such as vitamins, ozone, dentritic cells, natural killer and autologous cytokines that activate the immune system. Our realtionship with Cantech Holding is that they are part of our immunotherapy protocol at the moment that we give our patients their Immune-Therapeutic Protein (ITp) for our patients to continue the treatment back home. This is in order for the patient to keep up with a maintenance phase and continue activating their immune system.
If you are interested in our treatments, we kindly ask you to read more information about us in our website www.biomedicalcancercenter.com or send us an email with a medical history of the patient interested so we can give a more personalized protocol that is adequate for their condition.
We hope this information was helpful, please do not hesitate in contacting us if you have any further questions or concerns, we are happy to help.
Kind regards,
Cordialmente,
DR. JOSE RICARDO DUEÑAS . / Dra. GINA M. CASTELLANOS B.
Medicina Biológica Integrativa - Homotoxicología - Nutrición Clínica
Anti Envejecimiento - Medicina Estética
Consultorio: (664) 686 3177 - FROM U.S.A. (619) 270 5525
Calle Diego Rivera 2351, Cons. 604 - Zona Rio
Tijuana, B.C, Mexico 22010
Nice I agree this IS going to be huge. Better get your tickets soon folks and hold till well out of the trips!!